image description

Tag: Eric Morand

Summary Highlights of Important Research Presented at ACR Convergence 2023

November, 2023 At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is […] Read More

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] Read More

Positive Results on Anifrolumab for Lupus Published in New England Journal of Medicine

December 18, 2019 The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of Medicine online edition from AstraZeneca’s Phase 3 TULIP-2 trial studying the investigational biologic anifrolumab as a treatment for systemic lupus erythematosus (SLE or lupus).  The new study provides further details showing that anifrolumab, which targets […] Read More

Lupus Research Lifted Up in Everyday Health

May 27, 2021 Funding innovative research year-round is the most meaningful way the Lupus Research Alliance Lifts Up Lupus with the promise of better treatments and one day a cure. This excellent article in EVERYDAY HEALTH reports on eight of the most important discoveries in lupus of the past year, virtually all of which got […] Read More

LRA Researchers Star at ACR/ARP – Part 2

Last week we gave you only half the story of what scientists funded by the Lupus Research Alliance (LRA) shared at 2019 ACR/ARP. So many studies were presented that we needed to bring you Part 2 to expand our coverage of the major discoveries your donations have made possible. And a Part 3 is yet […] Read More

Lupus Research Alliance Response to Positive Data from Phase 3 Anifrolumab Trial Presented at 2019 ACR/ARP Annual Meeting

NEW YORK, NY – November 11. The Lupus Research Alliance (LRA) congratulates AstraZeneca on new positive results from the Phase 3 TULIP-2 trial (Treatment of Uncontrolled Lupus via the Interferon Pathway) presented at the 2019 ACR/ARP Annual Meeting.  The data showed that the investigational biologic treatment anifrolumab significantly reduced disease activity for people with lupus. […] Read More

Lupus Research Alliance-Funded Researchers Present Discoveries at ACR

October 29, 2018 More than 70 researchers who have received funding from the Lupus Research Alliance contributed to the scientific dialogue on lupus at the ACR|ARHP meeting this year. Following are highlights of specific discoveries the organization has supported: Tiring Out Rogue Cells Learning from cancer research, a team of scientists led by the inaugural […] Read More

Recognizing Remission in Lupus

October 30, 2018 Researchers are trying to ascertain the important issue in SLE of how much improvement in disease activity patients must show to decrease the long-term rate of organ damage.  Four studies presented at ACR by Drs. Eric Morand and Michelle Petri addressed that important question. Favorable Results for “Easier” Remission Target Three studies […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates